Griffin Asset Management, Inc. Regeneron Pharmaceuticals, Inc. Transaction History

Griffin Asset Management, Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 18, 2020	SELL	$336.18 - $494.43 $208,431 - $306,546	-620 Closed	0 $0
Q4 2019 Feb 11, 2020	BUY	$274.13 - $376.51 $169,960 - $233,436	620 New	620 $233,000
Q3 2019 Nov 05, 2019	SELL	$273.46 - $318.39 $198,258 - $230,832	-725 Closed	0 $0
Q4 2018 Mar 01, 2019	SELL	$335.82 - $403.04 $1.26 Million - $1.52 Million	-3,763 Reduced 83.85%	725 $271,000
Q3 2018 Nov 19, 2018	BUY	$351.14 - $408.51 $112,364 - $130,723	320 Added 7.68%	4,488 $1.81 Million
Q2 2018 Aug 15, 2018	BUY	$284.6 - $344.99 $197,797 - $239,768	695 Added 20.01%	4,168 $1.44 Million
Q1 2018 May 16, 2018	BUY	$315.82 - $393.78 $10,106 - $12,600	32 Added 0.93%	3,473 $1.2 Million
Q4 2017 Feb 20, 2018	SELL	$358.63 - $469.95 $32,276 - $42,295	-90 Reduced 2.55%	3,441 $1.29 Million
Q3 2017 Nov 15, 2017	BUY	$431.38 - $504.0 $1.52 Million - $1.78 Million	3,531	3,531 $1.58 Million

1,516

82.6M

1.22M

1.51M

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $73.1B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

Get notified when there are updates to the investment portfolio of Griffin Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Griffin Asset Management, Inc. with notifications on news.